-
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancerKorde, Larissa A. ...Neoadjuvant chemotherapy has been shown to be equivalent to post-operative treatment for breast cancer, and allows for assessment of chemotherapy response. In a pilot trial of docetaxel (T) and ... capecitabine (X) neoadjuvant chemotherapy for Stage II/III BC, we assessed correlation between baseline gene expression and tumor response to treatment, and examined changes in gene expression associated with treatment. Patients received four cycles of TX. Tumor tissue obtained from Mammotome core biopsies pretreatment (BL) and post-cycle 1 (C1) of TX was flash frozen and stored at -70 degrees C until processing. Gene expression analysis utilized Affymetrix HG-U133 Plus 2.0 GeneChip arrays. Statistical analysis was performed using BRB Array Tools after RMA normalization. Gene ontology (GO) pathway analysis used random variance t tests with a significance level of P < 0.005. For gene categories identified by GO pathway analysis as significant, expression levels of individual genes within those pathways were compared between classes using univariate t tests; those genes with significance level of P < 0.05 were reported. PAM50 analyses were performed on tumor samples to investigate biologic subtype and risk of relapse (ROR). Using GO pathway analysis, 39 genecategories discriminated between responders and non-responders, most notably genes involved in microtubule assembly and regulation. When comparing pre- and post-chemotherapy specimens, we identified 71 differentially expressed gene categories, including DNA repair and cell proliferation regulation. There were 45 GO pathways in which the change in expression after one cycle of chemotherapy was significantly different among responders and non-responders. The majority of tumor samples fell into the basal-like and luminal B categories. ROR scores decreased in response to chemotherapy; this change was more evident in samples from patients classified as responders by clinical criteria. (Abs. trunc. at 2000 ch.)Source: Breast cancer research and treatment. - ISSN 0167-6806 (Letn. 119, št. 3, 2010, str. 685-699)Type of material - article, component partPublish date - 2010Language - englishCOBISS.SI-ID - 26386393
Author
Korde, Larissa A. |
Lusa, Lara |
McShane, Lisa M. |
Lebowitz, Peter F. |
Lukes, LuAnne |
Camphausen, Kevin |
Parker, Joel S. |
Swain, Sandra M. |
Hunter, Kent |
Zojewski, Jo Anne
Topics
Breast Neoplasms |
Drug Therapy |
Pathology |
Genetics |
Chemotherapy, Adjuvant |
Gene Expression |
Biopsy |
Dna Repair |
Treatment Outcome |
Kemoterapija pomožna |
Biopsija |
Gensko izražanje |
Dojka, novotvorbe |
DNA, obnova |
Zdravljenje, izid
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|---|
Korde, Larissa A. | ![]() |
Lusa, Lara | 29917 |
McShane, Lisa M. | ![]() |
Lebowitz, Peter F. | ![]() |
Lukes, LuAnne | ![]() |
Camphausen, Kevin | ![]() |
Parker, Joel S. | ![]() |
Swain, Sandra M. | ![]() |
Hunter, Kent | ![]() |
Zojewski, Jo Anne | ![]() |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
Pickup location | Material status | Reservation |
---|
Please wait a moment.